PDL BioPharma (Nasdaq: PDLI) reports Q1 EPS of $0.02, 12 cents worse than estimates.(0.14) Revenues were $90.5 million vs. $103.25 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE